BayCom (BCML) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
Annual Meeting scheduled for June 16, 2026, at 2:30 p.m. PDT to address key corporate matters.
Proxy materials, including the Proxy Statement and Annual Report, are available online and by request.
Shareholders can vote online, by mail, or in person using their Control Number.
Voting matters and shareholder proposals
Election of nine directors, each for a one-year term, is on the agenda.
Advisory (non-binding) vote on executive compensation will be held.
Ratification of Baker Tilly US, LLP as independent auditor for fiscal year ending December 31, 2026.
Board recommends voting FOR all director nominees, FOR the say-on-pay proposal, and FOR auditor ratification.
Board of directors and corporate governance
Director nominees include Bhupen B. Amin, Christopher F. Baron, William J. Black, Jr., Harpreet S. Chaudhary, Dennis H. Guida, Jr., Lloyd W. Kendall, Jr., Robert G. Laverne, M.D., Syvia L. Magid, and Michael J. Perdue.
Latest events from BayCom
- Q1 2026 net income surged 43.5% to $8.2M, with improved margins, asset growth, and new leadership.BCML
Q1 202611 May 2026 - Annual meeting features leadership transition, board elections, and focus on governance and ESG.BCML
Proxy filing29 Apr 2026 - Q4 2025 earnings grew 37% sequentially on higher net interest income and lower credit loss provisions.BCML
Q4 202522 Jan 2026 - Director elections, say-on-pay, and auditor ratification headline a governance-focused agenda.BCML
Proxy Filing2 Dec 2025 - Annual meeting to vote on directors, executive pay, and auditor, with online proxy access.BCML
Proxy Filing2 Dec 2025 - Earnings declined on higher credit loss provisions, but capital and liquidity remain strong.BCML
Q3 20257 Nov 2025 - Q2 2024 net income fell 22% as margins compressed, but capital and deposits remained strong.BCML
Q2 202414 Oct 2025 - Earnings and net interest margin improved, with robust capital and higher nonperforming loans.BCML
Q2 202511 Aug 2025 - Q3 net loss widened to $16.8M; $182.2M cash on hand supports clinical pipeline into 2027.BCML
Q3 202413 Jun 2025